(Q35840625)

10 August 2017

1 reference

title

New strategies for basal insulin treatment in type 2 diabetes mellitus (English)

1 reference

10 August 2017

1 reference

George Dailey

1

1 reference

10 August 2017

publication date

1 June 2004

1 reference

10 August 2017

published in

Clinical Therapeutics

1 reference

10 August 2017

volume

26

1 reference

10 August 2017

issue

6

1 reference

10 August 2017

page(s)

889-901

1 reference

Pharmacologic therapy for type 2 diabetes mellitus

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990132-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990132-4

1 reference

7 January 2021

Early intensive insulin treatment for induction of long-term glycaemic control in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990132-4

7 January 2021

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990132-4

7 January 2021

Impact of long-term complications on quality of life in patients with type 2 diabetes not using insulin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990132-4

7 January 2021

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990132-4

7 January 2021

Thiazolidinediones for the prevention of diabetes in the non-obese diabetic (NOD) mouse: implications for human type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990132-4

7 January 2021

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990132-4

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990132-4

7 January 2021

Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28),Pro(B29)] in IDDM

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990132-4

7 January 2021

Pathogenesis of NIDDM. A balanced overview

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990132-4

7 January 2021

The UK Prospective Diabetes Study. UK Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990132-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990132-4

1 reference

7 January 2021

Stimulation of insulin release by non-sulfonylurea hypoglycemic agents: the meglitinide family

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990132-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990132-4

1 reference

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990132-4

1 reference

7 January 2021

Thiazolidinediones: an update.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990132-4

7 January 2021

Tactics for type II diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990132-4

7 January 2021

Newly diagnosed latent autoimmune diabetes in adults (LADA) is associated with low level glutamate decarboxylase (GAD65) and IA-2 autoantibodies. Diabetes Incidence Study in Sweden (DISS)

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990132-4

7 January 2021

Combining sulfonylureas and other oral agents

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990132-4

7 January 2021

The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990132-4

7 January 2021

Rosiglitazone in combination with glimepiride plus metformin in type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990132-4

7 January 2021

NIDDM patients' fears and hopes about insulin therapy. The basis of patient reluctance

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990132-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990132-4

1 reference

7 January 2021

Improved beta-cell function after intensive insulin treatment in severe non-insulin-dependent diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990132-4

7 January 2021

Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990132-4

7 January 2021

Combining insulin and oral agents

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990132-4

7 January 2021

Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990132-4

7 January 2021

Long-term glycaemic improvement after addition of metformin to insulin in insulin-treated obese type 2 diabetes patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990132-4

7 January 2021

Combination of insulin and metformin in the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990132-4

7 January 2021

Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990132-4

7 January 2021

Partial recovery of insulin secretion and action after combined insulin-sulfonylurea treatment in type 2 (non-insulin-dependent) diabetic patients with secondary failure to oral agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990132-4

7 January 2021

Diabetes: The quest for basal normoglycaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990132-4

7 January 2021

Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990132-4

7 January 2021

Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990132-4

7 January 2021

Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990132-4

7 January 2021

Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990132-4

7 January 2021

Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990132-4

7 January 2021

A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990132-4

7 January 2021

Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990132-4

7 January 2021

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990132-4

7 January 2021

A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990132-4

7 January 2021

10.1016/S0149-2918(04)90132-4

Identifiers

DOI

1 reference

10 August 2017

1 reference